Author: Healio ophthalmology

FDA gives greenlight for phase 2 study of travoprost with iDose delivery system

by  •  • 0 Comments

The FDA will allow Glaukos to initiate a U.S. investigational new drug phase 2 study of a travoprost intraocular implant with the iDose delivery system in patients with glaucoma, according to a press release. “We are very pleased that the FDA is allowing this trial to begin several months in advance of our original target date,” Thomas Burns, president and CEO of Glaukos, said in the release.

Read more →

Publication Exclusive: Pregnant woman presents with floaters and decreased vision

by  •  • 0 Comments

A 32-year-old pregnant woman at 31 weeks’ gestational age was referred to the New England Eye Center for a 1-week history of floaters and decreased vision in the left eye. She complained of 1 day of photophobia and left eye pain.Ocular history was unremarkable. Medical history included prior cesarean section, hepatitis C and spinal desmoid tumors resected and treated with doxorubicin. She had a history of intravenous drug use and stated the last episode was 8 months before presentation. She lived in a rural area with exposure to many animals (Read more...)

Valeant Pharmaceuticals names interim CEO

by  •  • 0 Comments

Valeant Pharmaceuticals International announced in a press release that it has appointed Howard B. Schiller as interim CEO.Schiller was Valeant’s chief financial officer from December 2011 through June 2015 and has served on Valeant’s Board of Directors since 2012, according to the release. J. Michael Pearson, Valeant’s CEO, is on medical leave of absence and remains in the hospital where he is being treated for pneumonia, and the timing of his expected return is uncertain, the release stated.

Read more →

William L. Rich III, MD, begins term as 2016 president of AAO

by  •  • 0 Comments

William L. Rich III, MD, has begun his term as the 119th president of the American Academy of Ophthalmology, according to a press release from the AAO.Rich, the AAO’s Medical Director of Health Policy, has more than 20 years of experience in health policy, health care financing and clinical quality metrics. He currently serves as chair of the AAO’s IRIS Registry committee and will continue to guide the implementation of the largest clinical data registry within any medical specialty during his term as president.

Read more →

Dry eye needs to be evaluated, managed before ocular surgery

by  •  • 0 Comments

Dry eye is a multifactorial disease of the tear film and ocular surface resulting in symptoms of discomfort, visual disturbance and tear film instability with potential ocular surface damage. It is accompanied by increased tear film osmolarity and ocular surface inflammation. This definition, given by the Dry Eye WorkShop in 2007, forms the basis of our understanding of dry eye. It also gives guidelines regarding grading of dry eye and treatment strategies for each grade of severity.When it comes to ocular surgeries, managing dry eye in the perioperative period plays (Read more...)

Bag-in-the-lens inventor reviews long-term outcomes, new developments

by  •  • 0 Comments

With more than 20,000 procedures performed worldwide and a follow-up of almost 12 years, bag-in-the-lens cataract surgery has proven to be a successful technique, with no cases of posterior capsule opacification, even in unusual cases.OSN Europe Edition Associate Editor Marie-José Tassignon, MD, PhD, who developed this method of cataract surgery with IOL implantation, has a personal experience of approximately 10,000 cases, performs bag-in-the-lens (BIL, Morcher) routinely and has patients come from all over Europe to be implanted with her technique.

Read more →

Alterações na superfície da LIO são incomuns, mas problemáticas

by  •  • 0 Comments

A natureza física de uma LIO depende principalmente do material do qual ela é feita. Apesar de as mudanças na superfície da cápsula da lente puderem se manifestar como opacificação capsular, como é frequentemente notado após a cirurgia de catarata, as mudanças na superfície da LIO não são comuns. Abrasões ópticas, dispersão de pigmento, descoloração e opacificação são as possíveis alterações superficiais que podem acontecer no óptico. Um óptico de 3 a 4 mm cobre a zona pupilar em uma situação anatômica normal; anormalidades superficiais nesta zona correm o risco (Read more...)

Alteraciones de LIO, poco comunes pero problemáticas

by  •  • 0 Comments

La naturaleza física de un LIO depende principalmente de su material. Si bien los cambios superficiales de la cápsula del lente pueden manifestarse como opacificación capsular, como suele encontrarse luego de la cirugía de cataratas, los cambios superficiales de los LIO son poco frecuentes. Las abrasiones ópticas, la dispersión de pigmentos, la decoloración y la opacificación son los cambios superficiales más comunes que puede sufrir la óptica. Una óptica de 3 mm a 4 mm cubre la zona de la pupila en una situación anatómica normal y las anomalías superficiales (Read more...)